Stay updated with breaking news from Thomas Biegi. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
EQS-News: MorphoSys AG / Key word: Change in Forecast MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022 21.10.2022 / 11:41... | October 21, 2022
EQS-News: MorphoSys AG / Key word(s): Change in Forecast MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financi...
EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monjuvi® (tafasitamab-cxix) for Patients with R/R DLBCL 28.09.2022 / 22:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media Release BOS...
BOSTON - MorphoSys USA, Inc., a fully owned subsidiary of MorphoSys AG , announced data from the ongoing L-MIND study showing that Monjuvi plus lenalidomide followed by Monjuvi monotherapy provided... | September 29, 2022
DGAP-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys appoints Tim Demuth as new Chief Research and Development Officer, following the retirement of Malte Peters 31.08.2022 / 22:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, August 31, 2...